Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1982 1
1984 1
1985 1
1986 4
1987 5
1988 3
1989 4
1990 5
1991 5
1992 6
1993 4
1994 2
1995 3
1996 5
1997 3
1998 4
1999 3
2000 2
2001 7
2002 3
2003 2
2004 4
2005 5
2006 11
2007 10
2008 11
2009 12
2010 16
2011 24
2012 29
2013 28
2014 17
2015 15
2016 18
2017 17
2018 12
2019 12
2020 13
2021 8
2022 7
2023 7
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

305 results

Results by year

Filters applied: . Clear all
Page 1
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. Fenaux P, et al. Among authors: list af. N Engl J Med. 2020 Jan 9;382(2):140-151. doi: 10.1056/NEJMoa1908892. N Engl J Med. 2020. PMID: 31914241 Free article. Clinical Trial.
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).
Bewersdorf JP, Xie Z, Bejar R, Borate U, Boultwood J, Brunner AM, Buckstein R, Carraway HE, Churpek JE, Daver NG, Porta MGD, DeZern AE, Fenaux P, Figueroa ME, Gore SD, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim TK, Komrokji R, Kuchroo VK, List AF, Loghavi S, Majeti R, Odenike O, Patnaik MM, Platzbecker U, Roboz GJ, Sallman DA, Santini V, Sanz G, Sekeres MA, Stahl M, Starczynowski DT, Steensma DP, Taylor J, Abdel-Wahab O, Xu ML, Savona MR, Wei AH, Zeidan AM. Bewersdorf JP, et al. Among authors: list af. Blood Rev. 2023 Jul;60:101072. doi: 10.1016/j.blre.2023.101072. Epub 2023 Mar 11. Blood Rev. 2023. PMID: 36934059 Review.
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
Stahl M, Bewersdorf JP, Xie Z, Porta MGD, Komrokji R, Xu ML, Abdel-Wahab O, Taylor J, Steensma DP, Starczynowski DT, Sekeres MA, Sanz G, Sallman DA, Roboz GJ, Platzbecker U, Patnaik MM, Padron E, Odenike O, Nimer SD, Nazha A, Majeti R, Loghavi S, Little RF, List AF, Kim TK, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Gore SD, Greenberg P, Figueroa ME, Fenaux P, Efficace F, DeZern AE, Daver NG, Churpek JE, Carraway HE, Buckstein R, Brunner AM, Boultwood J, Borate U, Bejar R, Bennett JM, Wei AH, Santini V, Savona MR, Zeidan AM. Stahl M, et al. Among authors: list af. Blood Rev. 2023 Nov;62:101128. doi: 10.1016/j.blre.2023.101128. Epub 2023 Aug 19. Blood Rev. 2023. PMID: 37704469 Review.
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.
Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali NH, Padron E, Korbel G, Attar EC, Kantarjian HM, Lancet JE, Fenaux P, List AF, Komrokji RS. Sallman DA, et al. Among authors: list af. J Clin Oncol. 2021 May 10;39(14):1584-1594. doi: 10.1200/JCO.20.02341. Epub 2021 Jan 15. J Clin Oncol. 2021. PMID: 33449813 Free PMC article. Clinical Trial.
Biological drivers of clinical phenotype in myelofibrosis.
Mascarenhas J, Gleitz HFE, Chifotides HT, Harrison CN, Verstovsek S, Vannucchi AM, Rampal RK, Kiladjian JJ, Vainchenker W, Hoffman R, Schneider RK, List AF. Mascarenhas J, et al. Among authors: list af. Leukemia. 2023 Feb;37(2):255-264. doi: 10.1038/s41375-022-01767-y. Epub 2022 Nov 24. Leukemia. 2023. PMID: 36434065 Free PMC article. Review.
Myelodysplastic syndromes.
Doll DC, List AF. Doll DC, et al. Among authors: list af. West J Med. 1989 Aug;151(2):161-7. West J Med. 1989. PMID: 2672599 Free PMC article. Review.
Functional hyposplenism.
Doll DC, List AF, Yarbro JW. Doll DC, et al. Among authors: list af. South Med J. 1987 Aug;80(8):999-1006. doi: 10.1097/00007611-198708000-00016. South Med J. 1987. PMID: 3303364 Review.
Lenalidomide--the phoenix rises.
List AF. List AF. N Engl J Med. 2007 Nov 22;357(21):2183-6. doi: 10.1056/NEJMe078203. N Engl J Med. 2007. PMID: 18032768 No abstract available.
Advances in the management of myelofibrosis.
Komrokji RS, Verstovsek S, Padron E, List AF. Komrokji RS, et al. Among authors: list af. Cancer Control. 2012 Oct;19(4 Suppl):4-15. doi: 10.1177/107327481201904s04. Cancer Control. 2012. PMID: 23042420 Free article. Review.
Myelodysplastic syndromes.
List AF, Vardiman J, Issa JP, DeWitte TM. List AF, et al. Hematology Am Soc Hematol Educ Program. 2004:297-317. doi: 10.1182/asheducation-2004.1.297. Hematology Am Soc Hematol Educ Program. 2004. PMID: 15561689 Review.
305 results